08:50 EDT Omeros (OMER) up 124% at $9.20 after entering license agreement for zaltenibert
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Novo Nordisk, Omeros enter asset purchase, license agreement for zaltenibert
- Omeros Corporation Completes Promising Phase 2 Study on OMS906 for PNH
- Promising Clinical Data and Unique Mechanism of Narsoplimab Justify Buy Rating
- Omeros announces publication of narsoplimab survival outcomes in TA-TMA
- Omeros Corporation’s Positive Earnings Call Highlights Progress